Spyre Therapeutics (SYRE) to Release Earnings on Thursday

Spyre Therapeutics (NASDAQ:SYRE) is expected to be issuing its Q1 2025 quarterly earnings data before the market opens on Thursday, May 8th. Analysts expect the company to announce earnings of ($0.74) per share for the quarter.

Spyre Therapeutics (NASDAQ:SYRE) last posted its quarterly earnings results on Thursday, February 27th. The company reported ($0.81) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.89) by $0.08. On average, analysts expect Spyre Therapeutics to post $-4 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Spyre Therapeutics Stock Performance

Shares of SYRE opened at $15.23 on Thursday. The stock has a market capitalization of $918.00 million, a PE ratio of -2.04 and a beta of 3.05. The company has a 50 day moving average price of $16.15 and a 200-day moving average price of $23.03. Spyre Therapeutics has a fifty-two week low of $10.91 and a fifty-two week high of $40.49.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on SYRE. Leerink Partnrs raised Spyre Therapeutics to a “strong-buy” rating in a research report on Tuesday, April 8th. Wedbush reaffirmed an “outperform” rating and set a $65.00 target price on shares of Spyre Therapeutics in a research report on Monday, January 13th. Leerink Partners assumed coverage on Spyre Therapeutics in a report on Tuesday, April 8th. They issued an “outperform” rating and a $45.00 price target for the company. The Goldman Sachs Group upgraded shares of Spyre Therapeutics to a “strong-buy” rating in a report on Tuesday, February 18th. Finally, Wolfe Research initiated coverage on shares of Spyre Therapeutics in a research note on Tuesday, March 18th. They issued an “outperform” rating and a $27.00 target price for the company. Eight analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat.com, Spyre Therapeutics currently has a consensus rating of “Buy” and an average target price of $49.57.

About Spyre Therapeutics

Spyre Therapeutics, Inc, a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease).